Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 PR Newswire - Thu Jul 9, 6:00AM CDT

FRIENDSWOOD, Texas , July 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will...

CSTL : 24.23 (+2.50%)
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy PR Newswire - Thu Jun 25, 3:30PM CDT

Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma...

CSTL : 24.23 (+2.50%)
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal PR Newswire - Tue Jun 23, 6:00AM CDT

Stokes was one of 22 financial leaders recognized in the Greater Houston area

CSTL : 24.23 (+2.50%)
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri Jun 19, 6:00AM CDT

FRIENDSWOOD, Texas , June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June...

CSTL : 24.23 (+2.50%)
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus PR Newswire - Tue Jun 16, 6:00AM CDT

FRIENDSWOOD, Texas , June 16, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...

CSTL : 24.23 (+2.50%)
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference PR Newswire - Wed May 13, 6:00AM CDT

FRIENDSWOOD, Texas , May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...

CSTL : 24.23 (+2.50%)
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation PR Newswire - Tue May 12, 6:00AM CDT

This marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing solutions

CSTL : 24.23 (+2.50%)
Castle Biosciences Reports First Quarter 2026 Results PR Newswire - Wed May 6, 3:05PM CDT

Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased...

CSTL : 24.23 (+2.50%)
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month PR Newswire - Tue May 5, 6:00AM CDT

Longstanding   collaborations with   AIM at Melanoma, the Melanoma Research Foundation,   The   Skin Cancer Foundation, IMPACT Melanoma and The   Sun Bus continue to   advance...

CSTL : 24.23 (+2.50%)
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus PR Newswire - Mon May 4, 6:00AM CDT

Clinical studies from Mayo Clinic researchers demonstrate the TissueCypher test provides improved risk stratification and influences risk-aligned surveillance decisions in clinical practice, with one study...

CSTL : 24.23 (+2.50%)

Barchart Exclusives

Bacon, Lettuce, and Tomato Season Is Almost Here. Lean Hog Prices Could Head Even Higher. Barchart - 5 minutes ago
October lean hog futures present a buying opportunity on more price strength. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.